Radiopharmaceuticals in Preclinical and Clinical Development for Monitoring of Therapy with PET

Por Dunphy, Mark PS., Lewis, Jason S.
Publicado em 2009

Role of FDG-PET scans in staging, response assessment, and follow-up care for non-small cell lung cancer

Por Cuaron, John, Dunphy, Mark, Rimner, Andreas
Publicado em 2013

Value of Second Opinion Review of Outside Institution PET-CT examinations

Por Ulaner, Gary A., Mannelli, Lorenzo, Dunphy, Mark
Publicado no Nucl Med Commun (2017)

Non-invasive metabolic imaging of brain tumors in the era of precision medicine

Por Kim, Michelle M., Parolia, Abhijit, Dunphy, Mark, Venneti, Sriram
Publicado no Nat Rev Clin Oncol (2016)

The Precision of Hepatic Arterial Infusion Scintigraphy as a Quantitative Biomarker of Tumor Microvasculature

Por Dunphy, Mark, Pandit-Taskar, Neeta, Fox, Josef J., Kemeny, Nancy
Publicado no AJR Am J Roentgenol (2017)

In Vivo Microcartography & Subcellular Imaging of Tumor Angiogenesis: a Novel Platform for Translational Angiogenesis Research

Por Dunphy, Mark P.S., Entenberg, David, Toledo-Crow, Ricardo, Larson, Steven M.
Publicado em 2009

Distribution of FDG-avid nodes in esophageal cancer: implications for radiotherapy target delineation

Por Garcia, Brandon, Goodman, Karyn A., Cambridge, Lajhem, Dunphy, Mark, Wu, Abraham J.
Publicado no Radiat Oncol (2016)

Dosimetry of (18)F-Labeled Tyrosine Kinase Inhibitor SKI-249380, a Dasatinib-Tracer for PET Imaging

Por Dunphy, Mark P. S., Zanzonico, Pat, Veach, Darren, Somwar, Romel, Pillarsetty, Nagavarakishore, Lewis, Jason, Larson, Steven
Publicado em 2012

Specialized second-opinion radiology review of PET/CT examinations for patients with diffuse large B-cell lymphoma impacts patient care and management

Por Sawan, Peter, Rebeiz, Karim, Schoder, Heiko, Batlevi, Connie, Moskowitz, Alison, Ulaner, Gary A., Dunphy, Mark, Mannelli, Lorenzo
Publicado no Medicine (Baltimore) (2017)

Chaperome heterogeneity and its implications for cancer study and treatment

Por Wang, Tai, Rodina, Anna, Dunphy, Mark P., Corben, Adriana, Modi, Shanu, Guzman, Monica L., Gewirth, Daniel T., Chiosis, Gabriela
Publicado no J Biol Chem (2019)

NIMG-72. PROGNOSTIC VALUE OF [(18)F]-FDG POSITRON EMISSION TOMOGRAPHY IN PATIENTS WITH RECURRENT GLIOBLASTOMA RECEIVING BEVACIZUMAB

Por Graham, Maya, Krebs, Simone, Bale, Tejus, Domfe, Kwaku, Lobaugh, Stephanie, Zhang, Zhigang, Dunphy, Mark, Kaley, Thomas, Young, Robert
Publicado no Neuro Oncol (2019)

Pharmacokinetic Assessment of (18)F-(2S,4R)-4-Fluoroglutamine in Patients with Cancer

Por Grkovski, Milan, Goel, Reema, Krebs, Simone, Staton, Kevin D., Harding, James J., Mellinghoff, Ingo K., Humm, John L., Dunphy, Mark P.S.
Publicado no J Nucl Med (2020)

Value of [(18)F]-FDG positron emission tomography in patients with recurrent glioblastoma receiving bevacizumab

Por Graham, Maya S, Krebs, Simone, Bale, Tejus, Domfe, Kwaku, Lobaugh, Stephanie M, Zhang, Zhigang, Dunphy, Mark P, Kaley, Thomas, Young, Robert J
Publicado no Neurooncol Adv (2020)

High-SUVmax on FDG-PET indicates pleomorphic subtype in epithelioid malignant pleural mesothelioma: Supportive evidence to reclassify pleomorphic as non-epithelioid histology

Por Kadota, Kyuichi, Kachala, Stefan S., Nitadori, Jun-ichi, Suzuki, Kei, Dunphy, Mark P. S., Sima, Camelia S., Travis, William D., Rusch, Valerie W., Adusumilli, Prasad S.
Publicado em 2012

Preoperative Consolidation-to-Tumor Ratio and SUVmax Stratify the Risk of Recurrence in Patients Undergoing Limited Resection for Lung Adenocarcinoma ≤2 cm

Por Nitadori, Jun-ichi, Bograd, Adam J., Morales, Eduardo A., Rizk, Nabil P., Dunphy, Mark P. S., Sima, Camelia S., Rusch, Valerie W., Adusumilli, Prasad S.
Publicado no Ann Surg Oncol (2013)

Detection of Recurrent Pancreatic Cancer: Value of Second-Opinion Interpretations of Cross-Sectional Images by subspecialized radiologists

Por Castellanos, Sandra Huicochea, Corrias, Giuseppe, Ulaner, Gary A., Dunphy, Mark, Zheng Junting, Capanu, Marinela, Balachandran, Vinod, Giancipoli, Romina Grazia, Monti, Serena, Mannelli, Lorenzo
Publicado no Abdom Radiol (NY) (2019)

Prognostic Value of Pre radiotherapy (18)F-FDG PET/CT Volumetrics in Limited-stage Small Cell Lung Cancer

Por Ong, Leonard T., Dunphy, Mark, Foster, Amanda, Woo, Kaitlin M., Zhang, Zhigang, Perez, Carmen, Pietanza, Maria, Rosenzweig, Kenneth, Gelblum, Daphna, Rimner, Andreas, Wu, Abraham J.
Publicado no Clin Lung Cancer (2015)

Adaptive neoadjuvant chemotherapy guided by (18)F-FDG-PET in resectable non-small-cell lung cancers: the NEOSCAN trial

Por Chaft, Jamie E., Dunphy, Mark, Naidoo, Jarushka, Travis, William D., Hellmann, Matthew, Woo, Kaitlin, Downey, Robert, Rusch, Valerie, Ginsberg, Michelle S., Azzoli, Christopher G., Kris, Mark G.
Publicado no J Thorac Oncol (2015)

FDG-PET SUVmax Combined with IASLC/ATS/ERS Histologic Classification Improves the Prognostic Stratification of Patients with Stage I Lung Adenocarcinoma

Por Kadota, Kyuichi, Colovos, Christos, Suzuki, Kei, Rizk, Nabil P., Dunphy, Mark P. S., Zabor, Emily C., Sima, Camelia S., Yoshizawa, Akihiko, Travis, William D., Rusch, Valerie W., Adusumilli, Prasad S.
Publicado em 2012

Radiosynthesis of the iodine-124 labeled Hsp90 inhibitor PU-H71

Por Taldone, Tony, Zatorska, Danuta, Ochiana, Stefan O., Smith-Jones, Peter, Koziorowski, Jacek, Dunphy, Mark P., Zanzonico, Pat, Bolaender, Alexander, Lewis, Jason S., Larson, Steven M., Chiosis, Gabriela, Pillarsetty, Nagavarakishore
Publicado no J Labelled Comp Radiopharm (2016)